Clinical Trials Browser

Terminated × Has results × Nivolumab × Clear all

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT04166383 2026-03-10

VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

Phase 2 Terminated

14 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT03785210 2026-02-23

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Phase 2 Terminated

22 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03366766 2026-02-20

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

14 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT04187404 2026-01-30

Spencer

Phase 1/2 Terminated

70 enrolled 20 charts

Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma

NCT02408861 2026-01-21

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Terminated

79 enrolled 24 charts

GastrointestinalSarcomaThoracic

Anus Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Sarcoma, Kaposi, HIV Infections

NCT03425331 2026-01-08

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

Phase 2 Terminated

5 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT05002569 2026-01-08

RELATIVITY-098

Phase 3 Terminated

1,093 enrolled 15 charts

Melanoma

NCT05846646 2025-10-20

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Phase 2 Terminated

6 enrolled 7 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT04050462 2025-10-16

Nivolumab Combined With BMS-986253 in HCC Patients

Phase 2 Terminated

13 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04458909 2025-10-03

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 3 Terminated

15 enrolled 17 charts

Nasopharyngeal Carcinoma

NCT05350501 2025-09-29

CLAUDE

Phase 2 Terminated

1 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT03446040 2025-09-18

An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Phase 1/2 Terminated

92 enrolled 31 charts

Advanced Cancer

NCT04149574 2025-09-16

CheckMate 7G8

Phase 3 Terminated

13 enrolled 11 charts

Urinary Bladder Neoplasms

NCT04695977 2025-09-05

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Phase 2/3 Terminated

20 enrolled 18 charts

Melanoma

NCT03646123 2025-08-28

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Phase 2 Terminated

255 enrolled 29 charts

Hodgkin Disease

NCT04057365 2025-08-13

Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)

Phase 2 Terminated

15 enrolled 8 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT04611126 2025-08-12

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Phase 1/2 Terminated

6 enrolled 11 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02681302 2025-07-25

CPIT001

Phase 1/2 Terminated

46 enrolled 13 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT03815942 2025-06-25

ADVANCE

Phase 1/2 Terminated

23 enrolled 11 charts

Intermediate Risk Prostate Cancer

NCT04698187 2025-06-11

CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

Phase 2 Terminated

44 enrolled 19 charts

Melanoma

NCT06003075 2025-04-30

Induction Chemo-Nivo in Unresectable Stage III NSCLC

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06094296 2025-04-16

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

1 enrolled 4 charts

Lung Neoplasms

NCT05543629 2025-03-18

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Phase 1/2 Terminated

36 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung

NCT03727061 2025-03-11

Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer

Phase 1 Terminated

5 enrolled 8 charts

Recurrent Head and Neck Carcinoma

NCT04322643 2025-02-25

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

4 enrolled 10 charts

Carcinoma, Transitional Cell

NCT03371381 2025-02-04

An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung

Phase 1/2 Terminated

12 enrolled 15 charts

Adenocarcinoma of Lung

NCT02702492 2024-11-25

PANAMA

Phase 1 Terminated

60 enrolled 22 charts

Melanoma

NCT05200143 2024-09-19

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Phase 2 Terminated

4 enrolled 11 charts

Melanoma

NCT03552380 2024-09-03

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

Phase 2 Terminated

12 enrolled 16 charts

Carcinoma, Renal Cell

NCT04159896 2024-07-16

ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Phase 2 Terminated

10 enrolled 8 charts

Prostatic Neoplasms

NCT03631641 2024-07-01

Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy

Phase 2 Terminated

3 enrolled 5 charts

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis

NCT02949843 2024-06-28

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Phase 2 Terminated

19 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT04655157 2024-05-23

QUAD01

Phase 1/2 Terminated

2 enrolled 12 charts

Melanoma

NCT03562507 2024-05-20

ERICA

Phase 2 Terminated

8 enrolled 11 charts

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT03502746 2024-05-14

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Phase 2 Terminated

34 enrolled 11 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02954991 2024-04-22

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Phase 2 Terminated

161 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT03311334 2024-04-18

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Phase 1/2 Terminated

47 enrolled 11 charts

GenitourinaryGynecologic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Kidney Neoplasms, Wilms Tumor, Ovarian Neoplasms

NCT02978443 2024-04-04

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Phase 2 Terminated

14 enrolled 12 charts

Melanoma

NCT04899921 2024-03-26

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Phase 2 Terminated

Melanoma

NCT03519308 2024-03-15

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Phase EARLY_PHASE1 Terminated

3 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02723006 2024-03-05

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

Phase 1 Terminated

22 enrolled 14 charts

Melanoma

NCT03461952 2024-02-22

NIMBLe

Phase 2 Terminated

4 enrolled 4 charts

Other solid neoplasm

Advanced Solid Tumors

NCT03495713 2024-01-17

Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS

Phase 2 Terminated

7 enrolled 7 charts

Hodgkin Disease

NCT03420521 2024-01-09

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Phase 2 Terminated

9 enrolled 17 charts

Carcinoid Tumor, Neuroendocrine Tumors

NCT02831933 2023-09-21

ENSIGN

Phase 2 Terminated

11 enrolled 9 charts

DermatologicThoracic

Uveal Melanoma, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT03606174 2023-08-24

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Phase 2 Terminated

260 enrolled 28 charts

Carcinoma, Transitional Cell

NCT04119336 2023-08-21

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

Phase 2 Terminated

2 enrolled 6 charts

Multiple Myeloma

NCT03662074 2023-08-02

Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer

Phase 2 Terminated

14 enrolled 14 charts

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03782064 2023-06-22

Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma

Phase 2 Terminated

5 enrolled 8 charts

Multiple Myeloma